Biohaven’s troriluzole rejected before FDA review
Biohaven said Thursday it received a refusal-to-file letter from the FDA over its NDA for troriluzole in an announcement that sent its share price down …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
